Your browser doesn't support javascript.
loading
Advances in the Pathophysiology of Thrombosis in Antiphospholipid Syndrome: Molecular Mechanisms and Signaling through Lipid Rafts.
Capozzi, Antonella; Manganelli, Valeria; Riitano, Gloria; Caissutti, Daniela; Longo, Agostina; Garofalo, Tina; Sorice, Maurizio; Misasi, Roberta.
Afiliación
  • Capozzi A; Department of Experimental Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.
  • Manganelli V; Department of Experimental Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.
  • Riitano G; Department of Experimental Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.
  • Caissutti D; Department of Experimental Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.
  • Longo A; Department of Experimental Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.
  • Garofalo T; Department of Experimental Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.
  • Sorice M; Department of Experimental Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.
  • Misasi R; Department of Experimental Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.
J Clin Med ; 12(3)2023 Jan 23.
Article en En | MEDLINE | ID: mdl-36769539
ABSTRACT
The pathological features of antiphospholipid syndrome (APS) are related to the activity of circulating antiphospholipid antibodies (aPLs) associated with vascular thrombosis and obstetric complications. Indeed, aPLs are not only disease markers, but also play a determining pathogenetic role in APS and exert their effects through the activation of cells and coagulation factors and inflammatory mediators for the materialization of the thromboinflammatory pathogenetic mechanism. Cellular activation in APS necessarily involves the interaction of aPLs with target receptors on the cell membrane, capable of triggering the signal transduction pathway(s). This interaction occurs at specific microdomains of the cell plasma membrane called lipid rafts. In this review, we focus on the key role of lipid rafts as signaling platforms in the pathogenesis of APS, and propose this pathogenetic step as a strategic target of new therapies in order to improve classical anti-thrombotic approaches with "new" immunomodulatory drugs.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2023 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2023 Tipo del documento: Article País de afiliación: Italia